Absci Corporation (ABSI)
| Market Cap | 861.18M +110.7% |
| Revenue (ttm) | 2.80M -38.2% |
| Net Income | -115.18M |
| EPS | -0.84 |
| Shares Out | 155.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,754,680 |
| Open | 5.81 |
| Previous Close | 5.95 |
| Day's Range | 5.60 - 6.04 |
| 52-Week Range | 2.24 - 6.24 |
| Beta | 2.37 |
| Analysts | Strong Buy |
| Price Target | 6.96 (+25.63%) |
| Earnings Date | May 7, 2026 |
About ABSI
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket... [Read more]
Financial Performance
In 2025, Absci's revenue was $2.80 million, a decrease of -38.24% compared to the previous year's $4.53 million. Losses were -$115.18 million, 11.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price target is $6.96, which is an increase of 25.63% from the latest price.
News
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generativ...
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generat...
Absci Transcript: 25th Annual Needham Virtual Healthcare Conference
AI-driven platform targets the prolactin receptor for AGA and endometriosis, with ABS-201 advancing through clinical trials and key readouts expected this year. Market research shows strong demand for durable, low-frequency treatments, and commercialization will blend physician and direct-to-consumer strategies.
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generat...
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Absci (ABSI) to $4.20 from $4.32 and keeps an Equal Weight rating on the shares after the company reported Q4 earnings and
Absci Earnings Call Transcript: Q4 2025
ABS-201 advanced in clinical trials for AGA and endometriosis, showing favorable safety and strong market interest. Q4 2025 saw increased R&D spending and a solid cash position, supporting operations into 2028 and ongoing strategic partnerships.
Absci reports Q4 EPS (20c), consensus (17c)
Reports Q4 revenue $650,000, consensus $1.38M. “Over the past year, we advanced ABS-201 from preclinical to three dosed cohorts in our HEADLINE trial with favorable emerging safety data, extending our
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data
AbSci Corp options imply 13.4% move in share price post-earnings
Pre-earnings options volume in AbSci (ABSI) Corp is normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 13.4%, or 40c, after results are
Options Volatility and Implied Earnings Moves Today, March 24, 2026
Today, several major companies are expected to report earnings: AAR (AIR), GameStop (GME), KB Home (KBH), Achieve Life Sciences (ACHV), Vertical Aerospace (EVTL), Draganfly (DPRO), AbSci (ABSI), Braze...
Absci Transcript: Leerink Global Healthcare Conference 2026
The platform leverages AI to develop assets for hard-to-target indications, with ABS-201 advancing in both AGA and endometriosis. Key clinical milestones are expected over the next 24 months, supported by strong financials and a focus on differentiated product profiles.
Absci appoints Ransi Somaratne as CMO
Absci (ABSI) announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci’s expanding ...
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue t...
Absci Transcript: TD Cowen 46th Annual Health Care Conference
Agentic AI is rapidly transforming drug discovery, with asset creation—especially ABS-201 for hair regrowth—seen as the main value driver. ABS-201 targets a $25B+ market, with efficient development and broad patient appeal, while the pipeline strategy balances internal development and early out-licensing.
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generati...
AMD discloses positions in Absci, Sanmina
AMD (AMD) in a regulatory filing disclosed its investments as of December 31, 2025, including positions in Absci (ABSI) and Sanmina (SANM). Absci shares are down fractionally at $2.55 in
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, to...
Absci Transcript: 44th Annual J.P. Morgan Healthcare Conference
Origin-1, a new AI model, enables rapid, cost-effective design of first-in-class antibodies for hard-to-drug targets. ABS-201 is advancing in trials for androgenic alopecia and endometriosis, with major readouts expected in the next 24 months. Market research shows strong demand and a multibillion-dollar opportunity.
Absci downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Absci (ABSI) to Equal Weight from Overweight with a price target of $4.32, down from $5.80. The latest company and pipeline disclosures have meaningfully increased the risk
Absci price target raised to $8 from $7 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Absci (ABSI) to $8 from $7 and keeps a Buy rating on the shares after the company hosted an investor event to
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, to...
Absci Transcript: Status Update
ABS-201, an AI-designed prolactin receptor antibody, targets a major unmet need in hair loss with robust preclinical efficacy, a favorable safety profile, and strong patient interest. The ongoing phase 1/2a trial aims for durable, convenient treatment, with a $25B+ U.S. market opportunity.
Absci’s ABS-201 shows efficacy in hair regeneration
Absci (ABSI) unveiled new preclinical data for ABS-201, an AI-designed antibody targeting the prolactin receptor. The data demonstrate that ABS-201 effectively stimulates hair growth by regenerating t...
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo
Absci, former U.S. soccer player Donovan announce partnership
Absci (ABSI) Corporation announced a partnership with U.S. soccer legend Landon Donovan to elevate the voices of those living with androgenetic alopecia, AGA, and shine a light on the emotional